Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.

about

Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.

Item

http://www.wikidata.org/entity/Q47914097

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Current strategies for the man ...... atients with multiple myeloma.

@en

Current strategies for the man ...... atients with multiple myeloma.

@nl

type

Item

label

Current strategies for the man ...... atients with multiple myeloma.

@en

Current strategies for the man ...... atients with multiple myeloma.

@nl

prefLabel

Current strategies for the man ...... atients with multiple myeloma.

@en

Current strategies for the man ...... atients with multiple myeloma.

@nl

P1476

Current strategies for the man ...... patients with multiple myeloma

@en

P2093

Taner Demirer

http://www.w3.org/2001/XMLSchema#string

Ugur Sahin

http://www.w3.org/2001/XMLSchema#string

P2860

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.

Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation.

Large-volume leukapheresis for peripheral blood progenitor cell collection in low body weight pediatric patients: a single center experience.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.

P304

357-370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCA.21591

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Q83591023

Taner Demirer

P577

2017-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28980709

http://www.w3.org/2001/XMLSchema#string